To determine the technical efficacy and safety of a flared polyurethane-covered self-expandable nitinol stent in the management of malignant biliary obstruction and to evaluate its clinical efficacy by estimating stent patency and patient survival rates.
THE insertion of a self-expanding metal stent has become a well-accepted palliative procedure to relieve malignant biliary obstruction (1) (2) (3) (4) (5) (6) .
The most common causes of stent occlusion are sludge formation, proximal and distal tumor overgrowth, tumor ingrowth, and stone formation (1, 7, 8) . The obstruction rates of uncovered stents vary from 5% to 100%, with a weighted mean of 22% (9) . The polyurethane-covered Wallstents that had been used in the treatment of malignant biliary obstruction were prone to premature occlusion in some cases and did not effectively prevent tumor ingrowth (10) . Recently, Nakamura et al (11) reported that polyurethanecovered Wallstents can be used to recanalize Wallstents obstructed by tumor ingrowth from malignant common bile duct (CBD) obstruction. Kanasaki et al (12) reported good results with polyurethane-covered nitinol Strecker stents for treatment of malignant biliary obstruction. Han et al (13) reported that the fully polyurethanecovered Niti-S stent (Taewoong, Seoul, Korea) had good results in the treatment of malignant biliary obstruction, but three patients showed stent migration proximally and distally. The flared polyurethane-covered self-expandable nitinol stent has some advantages in that the flared portion of the stent prevents its migration and the polyurethane covering prevents tumor ingrowth.
We present the results of a pilot study of flared polyurethane-covered Niti-S stents in patients with malignant biliary obstruction. This is a prospective, nonrandomized clinical study intended to determine the technical efficacy and safety of a flared polyurethane-covered self-expandable nitinol stent in the management of malignant biliary obstruction and to evaluate its clinical efficacy by estimating stent patency and patient survival rates.
MATERIALS AND METHODS

Patient Population
Of the 13 patients in this study, there were seven men and six women whose mean age was 65 years (range, 42-93 y). This study was approved by the institutional review board of our university and by the ethics committee of the Institute for Medical Science of University Hospital. The procedure was explained in detail to all prospective patients, and written ksconsent was obtained before the procedure. Inclusion criteria were (i) presence of malignant obstruction of the CBD below the hilar confluence caused by an unresectable malignant tumor or reocclusion of a previously placed self-expandable uncovered biliary stent and (ii) informed consent. Exclusion criteria included surgical resectability or a generally fatal patient condition such as sepsis or disseminated intracoagulopathy. All patients had percutaneous biliary drainage, for which nine were treated with a covered stent as the first stent and four were treated for failure of a standard uncovered stent.
In our study, there were biopsyconfirmed adenocarcinomas in seven patients; six patients lacked a confirmed biopsy result but had been diagnosed by abdominal spiral computed tomography and percutaneous cholangiography findings. The site of obstruction was the proximal CBD in nine patients, the middle CBD in two patients, and the distal CBD in two patients ( Table 1) .
Stent Device and Placement
The stents used in this study were self-expanding biliary Niti-S stents covered with polyurethane (Fig 1) . The flared, polyurethane-covered Niti-S stent is a commercial product made by the Taewoong Medical Corporation. The Niti-S stent is made from 0.007-inch nitinol wire, which has excellent biocompatibility and expansile force. It is a single-wire, selfexpandable stent without a sharp spur at either end (low-trauma ends). The flared portion of the stent is 12 mm in diameter and 10 mm in length, which prevents stent migration. The flared portion of the stent is always at the proximal aspect of the stent. First, the diameter and length of the nitinol stent to be used are determined in accordance with the size of the lumen into which the nitinol stent is to be implanted. Next, a glass tube is selected which has the same or a similar diameter as the nitinol stent. Accordingly, the stent is adhered onto the glass tube. The structure is then dipped in a container filled with a medical-grade polyurethane liquid (Taewoong). At this step, it should be noted that the glass tube and the selected stent are completely dipped in the polyurethane liquid, and the polyurethane is in contact with the glass tube through the stent. As a result, the stent is between the polyurethane layer formed at its outer surface and the polytetrafluoroethylene sheet formed at its inner surface. The selected stent sheathed with polyurethane is then removed from the container. The polyurethane is then subjected to heat-drying, and the glass tube is then pulled out from the stent. The polyurethane coating (0.03 mm thick) is nonporous and stable in organic solutions such as bile. To prevent stent migration, the outside of the stent is not dipped in the polyurethane solution. The flared end of the stent is not coated with polyurethane. The stents are 5-8 cm long when fully expanded to the maximum diameter of 10 mm in the covered portion and 12 mm in the flared portion. A 9-F introducer system was used. The stent was held, compressed, and elongated on a delivery catheter by a cylindrical rolling membrane (outer sheath). The delivery catheter has three markers, one in the first por- Flared polyurethane-covered self-expanding Niti-S stent endoprosthesis. The stent is a woven monofilament structure made of nitinol and partially covered with high-elasticity polyurethane. tion (proximal marker), the second in the actual stent length position (stent length marker), and the last in the distal position of the loaded stent (stent marker). To release the self-expanding stent, the outer sheath was pulled back under hydraulic support. The Niti-S stent shortened 51% after deployment, similar to the amount of shortening of Wallstents (50%). The stent has tungsten markers in the proximal and distal ends that help manipulation during deployment. Initially, standard percutaneous transhepatic cholangiography with a thin 21-gauge Chiba needle (Solco Intermed, Seoul, Korea) was performed under local anesthesia with 2% lidocaine HCl (Kwang Myung, Hwa Sung, Korea) and analgesia with 50 mg pethidine HCl (Myung Moon, Hwa Sung, Korea). The bile duct system was opacified with contrast medium. The length and configuration of the stenosis was documented. The obstructed biliary system was decompressed with an 8.5-or 10.2-F biliary drainage catheter (Cook, Bloomington, IN) in the form of external drainage. In most patients, stent placement was accomplished within 2 weeks after percutaneous transhepatic biliary drainage (PTBD). In three patients, stent placement was accomplished during the follow-up tubogram after extended duration of PTBD or stent placement. Depending on the extent of the tumor, a right intercostal and/or left epigastric approach was chosen. Stent insertion was performed over an extra-stiff Amplatz guide wire (180-cm length, 0.035-inch diameter, curved tip; Cook). Special attention was given so that the covered midportion of the stent was located exactly at the stricture. The distal end of the stent protruded 2-3 mm into the duodenum. Balloon dilation after stent insertion was not performed in any of the patients; rather, an 8.5-F or 10.2-F biliary drainage catheter was left in place for 7 days. The biliary drainage catheter was used for flushing and maintaining access to the biliary tree, not for drainage. Thereafter, imaging was repeated via the drainage catheter to check patency, function, and stent position. The catheter was removed if free bile flow into the duodenum was documented or bilirubin level was normalized or markedly decreased.
All patients received 200 mg prophylactic antibiotics administered intravenously over a period of 12 hours (Flomoxef sodium, Flumarin; Ildong, Ansung, Korea; or fosfomycin sodium; Fonofos, Chong Keun Dang, Chunan, Korea) before and usually 48 -72 hours after the procedure. Coagulation tests were performed before the procedure. If a patient had disseminated intravascular coagulopathy, stent placement was not performed.
Study Endpoints and Definitions
A hospital discharge report was obtained for each patient. The study endpoints were followed at monthly intervals for 2 years or until death. Sonography of the upper abdomen was performed, and bilirubin level was checked at each control examination. Follow-up also included telephone interviews with the referring physician or with the patient if he or she did not appear at the follow-up examination. If stent occlusion was suspected, the stent was revised percutaneously with use of a 10-F drainage catheter. Finally, the cause of death was ascertained for all patients who died within the observation period.
Successful decompression of the biliary system was defined by a decrease of serum bilirubin level by more than 30% versus baseline value within the first week after stent insertion (10). We measured the distance from the bifurcated line between the right and left intrahepatic ducts to the flared end of the biliary stent. Stent migration was defined as migration of the stent into the proximal portion of the CBD and the distal portion of duodenum and was established by comparison with the location of the flared end of the stent on initial imaging. Stent migration was classified as early migration within 1 week of follow-up and delayed migration 1 month after deployment. In cases of recurrent jaundice, stent occlusion was confirmed by sonography, percutaneous transhepatic cholangiography, or computed tomography (CT). Recurrent episodes of inexplicable fever were defined as cholangitis. At the time of death, the stent was assumed to be patent if the patient had normal or only mildly elevated serum bilirubin levels (Ͻ3 mg/dL). If the patient had obvious jaundice or had higher bilirubin levels than before the procedure, the stent was assumed to be obstructed. Ultrasonography (US) was used to examine the degree of stent occlusion. The echogenic materials in the stent were concluded to represent sludge formation. Floating material in the stent seen on the tubogram was also concluded to represent sludge formation.
Bilirubin and amylase/lipase levels before and during follow-up were analyzed statistically with use of the Wilcoxon signed-rank test. Stent patency and patient survival rates were calculated with use of Kaplan-Meier survival (life-table) analysis. The duration of primary patency of the stent was defined as the interval between stent placement and recurrence of obstructive jaundice. If obstruction was not evident during a patient's life, the patency period was considered to be equal to the survival duration but was censored.
RESULTS
Stent deployment was successful in all 13 patients (Table 1; Fig 2) . There was no proximal or distal stent migration during the procedure or follow-up period. The distance between the bifurcated line and the end of the flare portion of the stent immediately after stent placement was 5-25 mm (mean, 10 mm). One week later, the follow-up tubogram showed no change in distance (5-25 mm; mean, 10 mm) between the bifurcated line and the end of the flared portion of the stent. The follow-up plain radiographs did not change in any stent in right upper quadrant areas.
The mean bilirubin level decreased from 7.23 mg/dL Ϯ 5.01 (SD) before the procedure to 3.23 mg/dL Ϯ 2.54 at the first follow-up, which was statistically significant (Wilcoxon test, P Ͻ .01). There was no significant change in bilirubin levels between baseline values and those at the most recent follow-up after stent placement (P ϭ .861). The levels of amylase and lipase were 42.7 IU/L Ϯ 36. 4 The lesion was completely covered by the stent in two patients who received 5-cm-long stents. Four patients received 6-cm-long stents, four received 7-cm-long stents, and three received 8-cm-long stents. The stent was sufficiently long in all patients to cover the lesion. There were no cases of biliary side-branch obstruction except in the cystic duct.
One patient's stent was removed after 15 weeks with use of endoscopic guidance even though it functioned well because the endoscopist thought the stent might not be functioning well and that there had been erosion of the mucosa wall of the duodenum. It was very easy to remove the stent with endoscopic guidance with a grasping forceps. The covering membrane of the stent was not damaged. Two patients underwent PTBD because of tumor ingrowth in the proximal portion of the stent, as detected on the 16-and 18-week follow-up examinations (Fig   3) . One patient underwent PTBD for sludge formation in the stent noted during the 35-week follow-up (Fig 4) .
Duration of follow-up study in all patients was 8 -56 weeks (mean, 22.9 weeks). Ten patients died during weeks 8 -24 and three patients lived until weeks 38 -56. According to Kaplan-Meier survival analysis, the stent patency rates were 100%, 71%, and 48% at 10, 20, and 50 weeks, respectively (Fig 5) . The survival rates were 38% and 24% at 20 and 50 weeks, respectively (Fig 6) . The mean survival and patency durations were 25 weeks and 40 weeks, respectively. There were no procedure-related patient deaths identified; all deaths were from the natural course of the disease. The covered stents showed patent lumen formation in 10 patients; this was confirmed by laboratory values such as bilirubin level on the last day of the study.
DISCUSSION
The placement of a percutaneous self-expanding metal stent is an alternative to placement of an endoscopic polyethylene endoprosthesis in patients with malignant biliary obstruction (6) . It offers a higher success rate and longer prosthesis patency than a polyethylene prosthesis. However, long-term patency has been a major problem with uncovered stents. The most common causes of uncovered stent occlusion are sludge formation, proximal and distal tumor overgrowth, tumor ingrowth, and stone formation (1) (2) (3) (4) (5) (6) (7) (8) . The reported reobstruction rates of uncovered stents vary from 5% to 100%, with a weighted mean of 22% (9) . Use of covered biliary stents is common clinical practice in the management of malignant biliary obstructions (10 -19) . Partially or fully polyurethane-covered Wallstents, polyurethane-covered nitinol stents, and expanded polytetrafluoroethylene/fluorinated ethylene propylenecovered nitinol stents are usually used for treatment of malignant biliary obstruction. Biliary stents are currently made of nitinol, and the material usually used for the coating is polyurethane, which partially or fully covers the stent. Studies from recent literature reviewing covered stents are listed in Table 2 (10 -19) . The number of patients with covered stents placed for malignant biliary obstruction treatment ranged from four to 42 (mean, 18.5); technical success rates were between 80% and 100% (mean, 98%). The relative complications of the procedure included perihepatic bile leak in one patient and perihepatic and intrahepatic hematoma in one patient (19) . The 30-day mortality rates were between 0% and 20% (mean, 7.2%). The occlusion rates ranged from 0% to 37%, with a weighted mean of 14.7%. The early stent migration rates ranged from 0% to 20% (mean, 4.8%). The delayed stent migration rates ranged from 0% to 10% (mean, 1%). The incidence of cholangitis after stent deployment was 0%-11% (mean, 2.5%). The delayed complication rate indicated cholecystitis in 0%-12% of study patients (mean, 1.9%), pancreatitis in 0%-3% (mean, 0.3%), biloma in 0%-8% (mean, 1.1%), stent dislocation in 0%-10% (mean, 1%), and sludge formation in 0%-20% (mean, 2%). Follow-up examinations took place 16.9 -37.5 weeks after the procedure (mean, 23.3 weeks) (10 -19).
Hausegger et al (10) showed a 37% stent occlusion rate (11 of 30 patients), which represented tumor growth through the stent covering (n ϭ 2), distal tumor ingrowth (n ϭ 1), granulation tissue inside the stent (n ϭ 2), or unclear etiology (n ϭ 6). The stent occluded after 2 months in seven patients, after 4 months in two patients, and after 6 and 7 months in one patient each. Rossi et al (16) reported that seven of their 21 study patients with malignant biliary obstruction experienced stent occlusion, the principal cause of which was a tumor within the stent (n ϭ 4). This was confirmed by cholangioscopy, which indicated the presence of tumoral ingrowth. Born et al (14) reported four patients with stent dysfunction, which included three stent occlusions and one dislocation. Thurnher et al (15) found one partial reobstruction caused by sludge formation and stent migration (among five patients), which occurred in a patient one day after insertion. This patient was treated by insertion of another uncovered stent. Miyayama et al (17) reported one stent occlusion, which consisted of tumor growth above the upper stent edge, and partial distal stent migration, which occurred 3 days after stent placement, because the stent diameter was too small in relation to the dilated bile duct. Bezzi et al (18) had a 16% stent occlusion rate (four of 26), which represented obstruction above the proximal end of the stent (tumor overgrowth). Han et al (13) reported two cases of proximal migration. In their case of stenosis of the severe focal type, stent migration occurred in the widely dilated duct side. In the present study, there were two cases of stent occlusion in the flared portion of the covered stent. One patient underwent removal of the covered stent by endoscopy at 15-month follow-up, at which time the stent showed an intact polyurethane membrane. Follow-up durations and patency rates of covered stents have been varied (10 -19) . Hausegger et al (10) reported that the patency rates after 1, 3, 6, and 12 months were 96%, 69%, 47%, and 31%, respectively. Rossi et al (16) reported primary patency rates after 3, 6, and 9 months of 72%, 46%, and 46%, respectively. Both of these investigators (10, 16) reported that they did not have good patency rates because their stent occlusion rates were high (33%-37%). Born et al (14) noted that the mean survival of their patients was 6 months. Kanasaki et al (12) reported that the mean patency period of their stents was 37.5 weeks. Schöder et al (19) reported in a large group of covered stents that the primary patency rates at 3, 6, and 12 months were 90%, 76%, and 76%, respectively. In our study, the stent patency rates were 100%, 71%, and 48% at 10, 20, and 50 weeks, respectively. Born et al (12) and Kanasaki et al (14) reported good patency rates resulting from lower stent occlusion rates. However, such a comparison is difficult to make because each patient is treated at a difference stage of disease and tumors differ in histologic type, cellular growth, and biologic behavior (12) .
In fully or partially covered Wallstents, the advantages of the stent was that the radiopaque density was easily visible and there was ease of insertion and release of the stent at the site of obstruction (11, 15) . The disadvantage of this stent is that it is not optimal for hilar strictures involving the main right and left ducts. There was also distal stent migration, which could result in occlusion of side branches of the biliary duct, such as the cystic or pancreatic duct, with the subsequent risk of cholecystitis or pancreatitis (15) . To prevent migration of the partially covered Wallstent, 1 cm of its proximal or/and distal ends were left uncovered. The disadvantage of this approach is that the covering could be damaged during stent deployment and tissue could then grow through the damaged covering, which might not be as biologically stable as had been assumed and may have dissolved over time. Hausegger et al (10) speculated that the covering itself was associated with a higher stent reocclusion rate than was previously reported because the friction coefficient of the polyurethane surface was too high and increased the incrustation rate or triggered sludge formation. The advantage of the partially polyurethane Gianturco stent is that it shortens very little after its release and is highly radiopaque. The disadvantage of the Gianturco stent is its tendency to migrate (17) . The expanded polytetrafluoroethylene/fluorinated ethylene propylene-covered stent had several advantages. It was resistant to bacterial growth, which decreased the risk of occlusion caused by bile incrustation (18) . The nitinol wire has the advantage of remarkable flexibility and elasticity and good radial force. However, it has relatively low radiopacity, which is its single drawback. It consists of looped metal wires protruding from the external stent surface, which produce a direct mechanical resistance to migration. The disadvantage of the expanded polytetrafluoroethylene/ fluorinated ethylene propylene-covered stent is its large introducer system (10 F), which may cause blockage of the cystic duct, resulting in possible cholecystitis (18, 19) . The fully polyurethane-covered nitinol Strecker stent was associated with good results because of the advantages of its nitinol wire (12) . The fully polyurethane-covered nitinol stent also has the advantages of nitinol wire. It successfully prevented tumor ingrowth of the stent but was associated with a high rate of early stent migration (13) . The use of a polyester-type polyurethane membrane which is resistant to hydrolysis and is relatively stable biologically may function as a barrier against tumor ingrowth (17, 20) . The other main advantage of a polyester-type polyurethane membrane is its high efficacy relative to its modest cost. It has a high resistance to chemical agents and a low coefficient of friction. The disadvantage of polyester is that it has a lower elasticity force. It is also very difficult and expensive to coat an entire stent. In our cases, the Niti-S stent was coated with polyester-type polyurethane inside the stent, which caused it to differ from other types of polyurethane-covered stents (17, 20) .
In the flared polyurethane-covered nitinol stent, the flared portion of the stent (12 mm) is widely compared to the covered portion of the stent (10 mm), and the flared portion of stent is similar to an uncovered stent. The flared portion connects to the covered portion at a 15°shoulder formation, which can be anchored to the bile duct wall, thereby preventing stent migration. We did not have any stent migration proximally or distally. The flared free ends have two roles: to prevent stent migration by anchoring the action of their lower end and to permit stent placement in the right and left biliary ducts without obstructing the lateral branches of the intrahepatic duct.
The stent was designed to prevent migration of its flared portion and of the polyurethane membrane-coated inner aspect of the stent. The stent had polyurethane membranes to prevent tumor ingrowth, but a disadvantage of the stent is the possibility of tumor ingrowth into the flared portion of the stent.
In conclusion, a flared polyurethane-covered self-expandable nitinol stent is feasible and effective for the treatment of malignant biliary obstruction. It did not migrate, but it allowed tumor ingrowth into the flared portion of the stent.
